<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908514</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-629-PS-001</org_study_id>
    <nct_id>NCT04908514</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis</brief_title>
  <official_title>A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and&#xD;
      Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Assessment</measure>
    <time_frame>Safety Assessment Period (Day 1 - 85)</time_frame>
    <description>Adverse Event Collection</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-629</intervention_name>
    <description>ADX-629 administered orally twice daily (BID) for approximately 12 weeks.</description>
    <arm_group_label>ADX-629 250 mg administered orally twice daily (BID) for approximately 12 weeks.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a male or non-pregnant female 18 years of age or older.&#xD;
&#xD;
          -  Subject has provided written informed consent.&#xD;
&#xD;
          -  Females must be post-menopausal, surgically sterile, or use a highly effective method&#xD;
             of birth control during the trial and for 30 days after the last administration of&#xD;
             test article. Women of childbearing potential (WOCBP) must have a negative urine&#xD;
             pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline.&#xD;
&#xD;
          -  Male subjects who are not surgically sterile (e.g., vasectomy performed at least 6&#xD;
             months prior to trial entry) and are sexually active with a female partner who is of&#xD;
             childbearing potential must agree to use an effective form of birth control for the&#xD;
             duration of the trial and for 90 days after completion of treatment.&#xD;
&#xD;
          -  Subject, in the investigator's opinion, is in good general health and free of any&#xD;
             disease state or physical condition that might impair evaluation of plaque psoriasis&#xD;
             or exposes the subject to an unacceptable risk by trial participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant, lactating, or is planning to become pregnant during the trial.&#xD;
&#xD;
          -  Subject has a physical condition which, in the investigator's opinion, might impair&#xD;
             evaluation of plaque psoriasis or which exposes the subject to an unacceptable risk by&#xD;
             trial participation.&#xD;
&#xD;
          -  Subject is currently enrolled in an investigational drug, biologic, or device trial.&#xD;
&#xD;
          -  Subject has used an investigational drug, investigational biologic, or investigational&#xD;
             device treatment within 30 days prior to Visit 2/Baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bill Cavanagh</last_name>
    <phone>(781) 761-4904</phone>
    <email>bcavanagh@aldeyra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TCR Medical Corporation</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neal D. Bhatia, MD</last_name>
      <phone>858-571-6800</phone>
      <email>nbhatia@therapeuticsresearch.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

